Back

Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Novel targets and treatments for heart diseases and diabetes Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Mariam Elmegaard

Gentofte University Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on novel targets and treatments for heart diseases and diabetes
Professor J. Pernow (Stockholm, SE)
Slides
Presentation thumbnail
Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis
Abstract Slides Video
Presentation thumbnail
GLP1 receptor agonists exhibit antioxidant and anti-inflammatory properties in human heart tissue via the canonical GLP1 receptor expression through a AMPK-mediated pathway
Doctor E. Cordeanu (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis
Doctor R. Mentz (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Novel targets and treatments for heart diseases and diabetes
Video

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Hypertension and glucose
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources